Clinical Endoscopy

Jae Pil Han

2 Articles

The Early Onset of Disease May Be a Risk Factor for Decreased Bone Mineral Density in Patients with Inflammatory Bowel Disease: Hwa Jong Kim, Su Jin Hong, Young Woo Jeon, Jae Pil Han, Seung Hyo Han, Jee Heon Kang, Jae Woong Tae, Hee Sook Lim, Hee Kyung Kim, Bong Min Ko, Moon Sung Lee; Clin Endosc 2013;46(1):71-76. Published online January 31, 2013; DOI: https://doi.org/10.5946/ce.2013.46.1.71

Background/Aims

The pathogenesis of bone loss in patients with inflammatory bowel disease (IBD) is complex, multifactorial, and only partly understood. We aimed to examine the extent and risk factors of bone mass reduction and to analyze the impact of early onset of a disease before attaining peak bone mass in IBD patients.

Methods

We compared the risk factors for osteoporosis and BMD at the lumbar spine and the hip bone in IBD patients.

Results

A total of 44 patients with IBD were enrolled. Twenty-one and 23 patients were diagnosed as IBD before and after the age of 30 and designated as group A and group B, respectively. Group A had significant bone mass reduction at the lumbar spine than group B (BMD, 1.01±0.10 vs. 1.14±0.17, p<0.01; T-score, -1.22±0.84 vs. -0.08±1.39, p<0.01; Z-score, -1.11±0.81 vs. -0.03±1.32, p<0.01, respectively). Multivariate analysis showed that patients diagnosed as IBD before the age of 30 had possible risk factor of bone mass reduction (hazard ratio, 3.96; p=0.06).

Conclusions

Bone mass reduction was more severe in patients who were diagnosed with IBD before the age of 30 than in those diagnosed after the age of 30.

Citations

Citations to this article as recorded by

Small and Large Intestine (II): Inflammatory Bowel Disease, Short Bowel Syndrome, and Malignant Tumors of the Digestive Tract
Yolanda Ber, Santiago García-Lopez, Carla J. Gargallo-Puyuelo, Fernando Gomollón
Nutrients.2021; 13(7): 2325. CrossRef
Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan
Ichiro Takeuchi, Yoichiro Kaburaki, Katsuhiro Arai, Hirotaka Shimizu, Yuri Hirano, Satoru Nagata, Toshiaki Shimizu
Journal of Gastroenterology and Hepatology.2020; 35(4): 593. CrossRef
Advances in nutritional therapy in inflammatory bowel diseases: Review
Andrzej Wędrychowicz
World Journal of Gastroenterology.2016; 22(3): 1045. CrossRef
Nutritional aspect of pediatric inflammatory bowel disease: its clinical importance
Seung Kim, Hong Koh
Korean Journal of Pediatrics.2015; 58(10): 363. CrossRef
Biomarkers of Cartilage and Surrounding Joint Tissue
Anne S Siebuhr, Yi He, Natasja S Gudmann, Aurelie Gram, Cecilie F Kjelgaard-Petersen, Per Qvist, Morten A Karsdal, Anne C Bay-Jensen
Biomarkers in Medicine.2014; 8(5): 713. CrossRef
Crohn's disease and growth deficiency in children and adolescents
Marco Gasparetto
World Journal of Gastroenterology.2014; 20(37): 13219. CrossRef
Can Early Onset of Disease Be One of the Risk Factors for Low Bone Mineral Density in Patients with Inflammatory Bowel Disease?
Kwang An Kwon, Yang Suh Ku
Clinical Endoscopy.2013; 46(1): 5. CrossRef

6,632 View
60 Download
6 Web of Science
7 Crossref

A Hypereosinophilic Syndrome Presenting as Eosinophilic Colitis: Young Woo Jeon, Su Jin Hong, Hwa Jong Kim, Jae Pil Han, Hee Kyung Kim, Bong Min Ko, Sung Kyu Park, Moon Sung Lee; Clin Endosc 2012;45(4):444-447. Published online November 30, 2012; DOI: https://doi.org/10.5946/ce.2012.45.4.444

Abstract PDF PubReader ePub

Hypereosinophilic syndrome (HES) has three defining features: marked hypereosinophilia for at least 6 months, no confirmed etiology for the eosinophilia, and eosinophilia-related symptoms or organ dysfunction. However, a shorter period of hypereosinophilia with symptoms requiring eosinophil-lowering therapy is also acceptable. We report a case of HES presenting as eosinophilic colitis. Although hypereosinophilia was present for 3 months, this patient needed to be treated with eosionphil-lowering therapy for severe hematochezia. After systemic corticosteroid therapy, symptoms caused by organ involvement were dramatically improved.

Citations

Citations to this article as recorded by

Hyper-eosinophilic syndrome: An uncommon cause of chronic abdominal pain in an elderly male
Dibya L Praharaj, Bipadabhanjan Mallick, Preetam Nath, Sarat C Panigrahi, Anil C Anand, Rajkumar Sharma
Tropical Doctor.2021; 51(4): 640. CrossRef
Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease
Gregory M. Constantine, JeanAnne Ware, Thomas Brown, Lauren Thumm, Natasha Kamal, Sheila Kumar, David Kleiner, Irina Maric, Amy D. Klion
The Journal of Allergy and Clinical Immunology: In Practice.2020; 8(6): 2089. CrossRef
Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review
Vivian C. Nanagas, Anna Kovalszki
Clinical Reviews in Allergy & Immunology.2019; 57(2): 194. CrossRef
Hypereosinophilic Syndrome Presenting as Intussusception in Adults
Nuri Chon, WooJung Kim, Sang Young Park, Kwang Hyun Kim
Korean Journal of Medicine.2014; 87(5): 585. CrossRef
Syndrome hyperéosinophilique de type myéloprolifératif révélé par une ascite : à propos d’un cas
M. Boudabbous, H. Mnif, H. Bellaj, K. Yaïch, L. Chtourou, L. Mnif, A. Amouri, N. Tahri
Journal Africain d'Hépato-Gastroentérologie.2014; 8(2): 89. CrossRef
Recurrent cutaneous necrotizing eosinophilic vasculitis: a case report and review of the literature
Wenfei Li, Wang Cao, Haiyan Song, Yanxia Ciu, Xianmei Lu, Furen Zhang
Diagnostic Pathology.2013;[Epub] CrossRef

8,318 View
59 Download
6 Crossref

Author index